Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imaging Modalities for Melanoma Screening and Diagnosis
NCT03699995Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- May 2018
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Open-label, single-arm trial, sponsored by OHSU Knight Cancer Institute. Primary endpoints: Sensitivity of the imaging modalities at 1 year and Specificity of imaging modalities at 1 year. Started May 2018; status: terminated.
Beyond the preview
Go deeper on NCT03699995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03699995.